48TH FLOOR, CHEUNG KONG CENTER, HONG KONG, K3
Total Voting Rights
Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
Highlights Data to be Presented at AACR Annual Meeting 2026
ANNUAL GENERAL MEETING
Initiates Phase III Trial of HMPL-760 in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma in China
Vesting of awards under the Long Term Incentive Plan
Announces Update on Licensed Oncology Product TAZVERIK® in China
Intended Retirement of Independent Non-executive Director and Changes of Composition of Board Committees
Annual and Transition Report of Foreign Private Issuers
Amended Annual and Transition Report of Foreign Private Issuers
Prospectus filed pursuant to Rule 424(b)(5)
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
No filings found
Initial Statement of Beneficial Ownership
Submission Upload
Correspondence
Automatic Shelf Registration Statement for Securities of Certain Foreign Private Issuers and Certain Canadian Issuers, Offered on a Continuous Basis